Business

Title Due Date Maximum Award Amount Sort descending Description
Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) Varies

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343219
BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed) Varies

This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals. This FOA is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. This will support iterative improvement of molecular payloads capable of monitoring and manipulating neural cell activity and that can be delivered to specific brain cell types using targeting technologies.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343315
BRAIN Initiative Cell Atlas Network (BICAN): Comprehensive Center on Human and Non-human Primate Brain Cell Atlases (UM1 Clinical Trial Not Allowed) Varies

This Funding Opportunity Announcement (FOA) intends to support a group of large-scale Comprehensive Centers that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases of human and non-human primates with an emphasis on human. The Centers are expected to characterize all brain cell types (neurons, glia, and other non-neuronal cells) at high-resolution. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343915
Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed) Varies

The scientific objective of this Funding Opportunity Announcement is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune activation may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations, as well as identify novel therapies to target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation aroused in these processes.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344374
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344753
Genomic Community Resources (U24 Clinical Trial Not Allowed) Varies

The purpose of this initiative is to facilitate genomic research and to disseminate its products to the broader biomedical research community. NHGRI supports both new and existing genomic resources of demonstrated broad value to the research community. Awards under this FOA will support the development and distribution of genomic resources that will be valuable for both basic and clinical genomics research. Such resources include, but are not limited to, those that support: Genomic informatics toolsets, such as biomedical ontologies and analysis toolsets. Comprehensive identification and collections of genomic features, such as functional genomic elements and genetic assay results. Genomic community building efforts, such as standards development. Sample repositories for genomic studies, such as cell line repositories for high-value samples.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=346565
Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional) Varies

The NIH ?Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=346914
Island Energy Lighting Rebate Program No Due Date Given Varies

Island Energy offers rebates for installing specific lamps and fixtures within your commercial facility.  Click the links below for more information.

  • Commercial Lighting Rebate Catalog
  • Lighting Tracking Spreadsheet
  •  Motor and Process Improvement Program
  • Compressed Air Systems
https://islandenergy.com/rebates-special-programs/lighting-rebate-program/
Colusa County APCD FARMER Program No Due Date Given Varies

The Funding Agricultural Replacement Measures for Emission Reductions (FARMER) Program provides funding through local air districts for agricultural equipment, agricultural pump engines, tractors, and other equipment used in agricultural operations. The FARMER Program is supported in part by California Climate Investments, a statewide program that puts billions of Cap-and-Trade dollars to work.

https://www.countyofcolusa.org/845/Grant-Programs
Tehama County APCD Carl Moyer and FARMER Program No Due Date Given Varies

The Tehama County Air Pollution Control District (Air District) is currently accepting application packets for Year 22 of the Carl Moyer Program and Year 3 of the FARMER Program. 

In Tehama County the Carl Moyer Program and FARMER Program provide grant funding for qualifying projects. Applicants must obtain approval and have a signed, executed contract from the Air District prior to purchase and installation of any qualifying equipment. Any equipment purchased or installed prior to contract execution is ineligible. Please note that the Carl Moyer Program and FARMER Program are NOT rebate programs.

https://www.tehcoapcd.net/carl-moyer-program/